done@schemacareen.com Subject: Your confirmation is appreciated Tax Package Prepared For Carlos.Arriba Date of Issue: 04/30/14 From: Internal Revenue Service Due to a higher percentage of American taxpayers unable to pay their taxes, significant relief is being issued on the last day of April. View Your Approved Relief Amount   Continue here if you wish to completely stop-getting these alerts. You may also write to 15500.SW_Jay|St.-Beaverton|Oregon| 97006-6018 end these here http://loop.schemacareen.com/786214467ab1/2288760=89935698 or write 1088+colony+park+drivememphis+tn+38118-2090 EVGCOBITDFFTC other ARV drugs BIII T20 BIIIETR BIII FPV unboosted BIIIIDV unboosted BIIIIDV RTVboosted BIIINFV BIRTV as sole PI BIIISQV unboosted BId4T 3TC BITPV RTVboosted BIKey to Abbreviations 3TC lamivudine, ABC abacavir, ART antiretroviral therapy, ARV antiretroviral, COBI cobicistat, d4T stavudine, ddI didanosine, DLV delavirdine, DRV darunavir, ETR etravirine, EVG elvitegravir, FPV fosamprenavir, FTC emtricitabine, GI gastrointestinal, IDV indinavir, MVC maraviroc, NFV nelfinavir, NRTI nucleoside reverse transcriptase inhibitor, PI protease inhibitor, RTV ritonavir, SQV sacquinavir, T20 enfuvirtide, TDF tenofovir disoproxil fumarate, TPV tipranavir, ZDV zidovudineGuidelines for the Use of Antiretroviral Agents in HIV1Infected Adults and AdolescentsF20Downloaded from httpaidsinfo.nih.govguidelines on 11122013References1. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three vs fourdrug antiretroviral regimens for the initial treatment of HIV1 infec! tion a randomized controlled trial. JAMA. 20062967769781. Available at httpwww.ncbi.nlm.nih.goventrezquery.fcgicmdRetrievedbPubMeddoptCitationlistuids16905783. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviralnaive patients a 3year randomized trial. JAMA. 20042922191201. Available at httpwww.ncbi.nlm.nih.goventrezquery.fcgicmdRetrievedbPubMeddoptCitationlistuids15249568. Staszewski S, MoralesRamirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV1 infection in adults. Study 006 Team. N Engl J Med. 19993412518651873. Available at httpwww.ncbi.nlm.nih.goventrezquery.fcgicmdRetrievedbPubMeddoptCitationlistuids10601505. Riddler SA, Haubrich R, DiRienzo AG, et al. Classsparing regimens for initial treatment of HIV1 infection. N Engl J Med. 20083582020952106. Available at httpwww.ncbi.nl! m.nih.goventrezquery.fcgicmdRetrievedbPubMeddoptCitationlistuids18480202. Squires K, Lazzarin A, Gatell JM, et al. Comparison of oncedaily atazanavir with efavirenz, each in combination with fixeddose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 200436510111019. Available at httpwww.ncbi.nlm.nih.goventrezquery.fcgicmdRetrievedbPubMeddoptCitationlistuids15247553. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravirbased versus efavirenzbased combination therapy in treatmentnaive patients with HIV1 infection a multicentre, doubleblind randomised controlled trial. Lancet. 20093749692796806. Available at httpwww.ncbi.nlm.nih.goventrezquery.fcgicmdRetrievedbPubMeddoptCitationlistuids19647866. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudinelamivudine, for the treatment of antiretroviralnaive subjects with CCR5tropic HIV1 infection. J Infect D! is. 20102016803813. Available at httpwww.ncbi.nlm.nih.goventrezquery.fc! gicmdRetrievedbPubMeddoptCitationlistuids20151839. Sax PE, Tierney C, Collier AC, et al. Abacavirlamivudine versus tenofoviremtricitabine for initial HIV1 therapy. N Engl J Med. 20093612322302240. Available at httpwww.ncbi.nlm.nih.goventrezquery.fcgicmdRetrievedbPubMeddoptCitationlistuids19952143. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with oncedaily abacavirlamivudine versus tenofoviremtricitabine, administered with efavirenz, in antiretroviralnaive, HIV1infected adults 48week results from the ASSERT study. J Acquir Immune Defic Syndr. 20105514957. Available at httpwww.ncbi.nlm.nih.goventrezquery.fcgicmdRetrievedbPubMeddoptCitationlistuids20431394.2.3.4.5.6.7.8.9.10. Smith KY, Patel P, Fine D, et al. Randomized, doubleblind, placebomatched, multicenter trial of abacavirlamivudine or tenofoviremtricitabine with lopinavirritonavir for initial HIV treatment. AIDS. 2009231215471556. Available at httpwww.ncbi.nlm.ni! h.goventrezquery.fcgicmdRetrievedbPubMeddoptCitationlistuids19542866. 11. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviralnaive persons randomized to receive abacavirlamivudine or tenofovir disoproxil fumarateemtricitabine along with efavirenz or atazanavirritonavir Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 20112031217911801. Available at httpwww.ncbi.nlm.nih.goventrezquery.fcgicmdRetrievedbPubMeddoptCitationlistuids21606537. 12. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 20063543251260. Available at httpwww.ncbi.nlm.nih.goventrezquery.fcgicmdRetrievedbPubMeddoptCitationlistuids16421366. 13. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3drug regimen for initial treatment of HIV1. Ann Intern Med. 20111547445456. Available at httpwww.ncbi.nlm.nih.govpub! med21320923. Guidelines for the Use of Antiretroviral Agents in HIV1Inf! ected Adults and Adolescents F21Downloaded from httpaidsinfo.nih.govguidelines on 11122013